EORTC Risk Model to Predict Progression in Patients With Non–Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?

Micro-Abstract We sought to validate the European Organization for Research and Treatment of Cancer (EORTC) risk tables to predict disease progression in Brazilian patients with non–muscle-invasive bladder cancer (NMIBC). Data from 205 prospectively selected patients were analyzed over 12 years. Tim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical genitourinary cancer 2016-04, Vol.14 (2), p.176-182
Hauptverfasser:	Busato Júnior, Wilson F.S, Almeida, Gilberto Laurino, Ribas, Carmen A.P.M, Ribas Filho, Jurandir M, De Cobelli, Ottavio
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Brazil Disease Progression Female Hematology, Oncology and Palliative Medicine Humans Male Middle Aged Neoplasm Recurrence, Local - epidemiology Non–muscle-invasive bladder cancer Prediction Progression Proportional Hazards Models Recurrence Risk Assessment Survival Analysis Urinary Bladder Neoplasms - pathology Urology Validation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract We sought to validate the European Organization for Research and Treatment of Cancer (EORTC) risk tables to predict disease progression in Brazilian patients with non–muscle-invasive bladder cancer (NMIBC). Data from 205 prospectively selected patients were analyzed over 12 years. Time to progression, risk score, and progression probabilities were calculated and compared to the EORTC model. The EORTC model successfully stratified progression risks in our cohort. This scoring system is useful in predicting progression and in helping to define treatment and follow-up in NMIBC patients.
ISSN:	1558-7673 1938-0682
DOI:	10.1016/j.clgc.2015.09.005